Published • loading... • Updated
Lilly Allies with BioArctic; Antengene and Insilico Sign Deals
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Lilly allies with BioArctic; Antengene and Insilico sign deals
Plus news about Denali, Nuvectis Pharma, Graph Therapeutics, GondolaBio and the Novo Nordisk Foundation. 🔗 Eli Lilly’s alliance with BioArctic: The Indianapolis drug giant will work with the Swedish biotech behind Eisai and Biogen’s ...
BioArctic signs potential $1bn Alzheimers research deal with Eli Lilly - European Biotechnology Magazine
BioArctic AB has signed a research and collaboration agreement with Eli Lilly potentially worth $1 billion, researching a new treatment combining BioArctic's proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration. The post BioArctic signs potential $1bn Alzheimers research deal with Eli Lilly appeared first on European Biotechnology Magazine.
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
FactualityÂ
To view factuality data please Upgrade to Premium
